Office-based Vision Therapy for Improving Reading and Attention in Children With Convergence Insufficiency

Summary

CITT-ART is a multicenter study (8 locations around the United States) of 324 children ages 9 to \<14 years with symptomatic convergence insufficiency (CI). The purpose of this study is to see if office-based therapy for convergence insufficiency (CI) improves reading ability and attention. CI is an eye-teaming problem where the eyes would like to drift outward when reading or doing close work. When eyes drift out, double vision can happen. To prevent double vision one must use extra effort to keep the eyes from going out. This extra effort can cause symptoms that can interfere with reading and working comfortably at near. These symptoms often include eyestrain, blurred vision, headaches, double vision, and loss of place when reading or performing tasks at near. In a prior study we found that therapy improves these symptoms. In this study we are looking at whether the therapy improves reading and attention

Conditions

• Convergence Insufficiency

Interventions

PROCEDURE

Office-based vergence/accommodative therapy

The OBVAT program has been divided into 4 phases. Within each phase there are a number of categories such as gross convergence, vergence, and accommodation. The therapy procedures in each category have been arranged sequentially from easiest to most difficult

Sponsors & Collaborators

• National Eye Institute (NEI)

  collaborator NIH

• Marshall B. Ketchum University

  collaborator UNKNOWN

• Ohio State University

  collaborator OTHER

• University of Alabama at Birmingham

  collaborator OTHER

• State University of New York College of Optometry

  collaborator OTHER

• Akron Children's Hospital

  collaborator OTHER

• Nova Southeastern University

  collaborator OTHER

• Bascom Palmer Eye Institute

  collaborator OTHER

• Salus University

  lead OTHER

Principal Investigators

• Mitchell Scheiman, OD · Salus University

• Lynn MItchell, MAS · Ohio State University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

9 Years

Max Age

13 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2014-05-31

Primary Completion

2017-07-31

Completion

2020-11-30

Countries

• United States

Study Locations